Get the Stockscreener App
1.67
3.47%
-0.06
After Hours:
1.71
0.04
+2.40%
Cardiff Oncology Inc stock is traded at $1.67, with a volume of 581.38K.
It is down -3.47% in the last 24 hours and down -14.80% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
See More
Previous Close:
$1.73
Open:
$1.72
24h Volume:
581.38K
Relative Volume:
0.53
Market Cap:
$114.17M
Revenue:
$593.00K
Net Income/Loss:
$-45.85M
P/E Ratio:
-2.4326
EPS:
-0.6865
Net Cash Flow:
$-37.97M
1W Performance:
-8.24%
1M Performance:
-14.80%
6M Performance:
-18.93%
1Y Performance:
-52.82%
1-Day Range:
$1.67
$1.755
1-Week Range:
$1.67
$1.87
52-Week Range:
$1.48
$4.555
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
1.67 | 118.27M | 593.00K | -45.85M | -37.97M | -0.6865 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | Noble Capital Markets | Outperform |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Vanguard (NASDAQ: CRDF) reports 0 shares after Jan 12, 2026 realignment - Stock Titan
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target - Investing.com
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy - Investing.com
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDF: Onvansertib plus FOLFIRI+BEV achieved a 72% response rate and strong PFS in RAS mutated CRC - TradingView
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar - Yahoo Finance
Cardiff Oncology Inc to Host KOL Webinar Transcript - GuruFocus
Published on: 2026-03-26 02:49:36 - baoquankhu1.vn
Earnings Update: Can Cardiff Oncology Inc reach all time highs this yearQuarterly Portfolio Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - ChartMill
Cardiff Oncology to present preclinical data at cancer conference By Investing.com - Investing.com Canada
Cardiff Oncology to present preclinical data at cancer conference - Investing.com
Cardiff Oncology Presents Promising Preclinical Data on Onvansertib at AACR Annual Meeting 2026 - Quiver Quantitative
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting - ChartMill
Levels Update: Can Cardiff Oncology Inc reach all time highs this year - baoquankhu1.vn
Ladenburg Thalmann Initiates Coverage of Cardiff Oncology (CRDF) with Buy Recommendation - MSN
IPO Launch: Whats the analyst consensus on Cardiff Oncology IncWeekly Trade Review & High Conviction Trade Alerts - baoquankhu1.vn
Jobs Data: Is Cardiff Oncology Inc undervalued by DCF analysisWeekly Investment Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn
Rate Cut: Can Cardiff Oncology Inc reach all time highs this yearPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Cardiff Oncology (STU:XE7C) NonCurrent Deferred Revenue : €0.00 Mil (As of Dec. 2025) - GuruFocus
What is Zacks Research’s Forecast for CRDF FY2027 Earnings? - Defense World
What is Zacks Research's Forecast for CRDF FY2027 Earnings? - MarketBeat
CRDF Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cardiff Oncology (NASDAQ:CRDF) Upgraded at Wall Street Zen - MarketBeat
Cardiff Oncology, Inc. (CRDF) - Minichart
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
HC Wainwright Issues Optimistic Outlook for CRDF Earnings - MarketBeat
Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewswire
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC - Defense World
CRDF: Onvansertib shows 72% ORR and robust PFS in RAS-mutated mCRC, advancing to phase III trials - TradingView
Piper Sandler Has Lowered Expectations for Cardiff Oncology (NASDAQ:CRDF) Stock Price - MarketBeat
CRDF: Today's Analyst Ratings and Price Target Adjustment | CRDF Stock News - GuruFocus
Cardiff Oncology advances onvansertib program in colorectal cancer - TipRanks
3 ‘Strong Buy’ Stocks to Buy Today, 2/25/2026, According to Top Analysts - TipRanks
Onvansertib Phase 2 results boost Cardiff Oncology (NASDAQ: CRDF) plans - Stock Titan
Cardiff Oncology Reports Full Year 2025 Results And Provides Business Update - Nasdaq
Cardiff Oncology Q4 2025 Results: Loss of $7.2M Beats Analyst Forecasts | Financial ReportNews and Statistics - IndexBox
Cardiff Oncology earnings beat by $0.08, revenue topped estimates - Investing.com Canada
Cardiff Oncology (NASDAQ:CRDF) Announces Quarterly Earnings Results - MarketBeat
Cardiff Oncology: Fourth Quarter Financial Results Overview - Bitget
Cardiff Oncology: Q4 Earnings Snapshot - marketscreener.com
Onvansertib Phase 2 results and 2025 loss at Cardiff Oncology (NASDAQ: CRDF) - Stock Titan
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update - GlobeNewswire
Cardiff cancer drug hits 72% response in metastatic colorectal trial - Stock Titan
Cardiff Oncology, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Cardiff Oncology Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - ChartMill
Market Wrap: Does Cardiff Oncology Inc have consistent dividend growthEarnings Recap Report & Growth Focused Stock Reports - baoquankhu1.vn
Cardiff Oncology (CRDF) interim CEO awarded 200,000 stock options - Stock Titan
Why Cardiff Oncology Inc. (XE7C) stock could be next leaderWeekly Trend Recap & Growth Focused Stock Reports - mfd.ru
Can Cardiff Oncology Inc. stock reach $100 price targetMarket Activity Recap & Safe Entry Trade Signal Reports - mfd.ru
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):